CA-CLOUDBLUE
31.3.2021 15:02:06 CEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company, has completed the acquisition and integration of Harmony Business Systems (HBS). Its comprehensive professional services automation (PSA) and revenue management software is now a complement to CloudBlue’s portfolio of services designed to simplify and accelerate resellers’ transition to an everything-as-a-service business.
As a CloudBlue company, UK-based HBS will independently operate HarmonyPSA, to serve customers around the world. Launched over a decade ago and with customers in 15 countries, the platform features multi-language support and enjoys one of the highest customer satisfaction ratings in the industry. It was purpose-built to manage any type of service by unifying sales, operations and finance functions. HarmonyPSA combines CRM, ticketing, storefront, lead generation, assisted sales, and vendor competency and incentive programs into a single solution as a quote to cash and accounting system. It is now available for the first time on the UK Ingram Micro Cloud Marketplace.
Resellers will have a dedicated instance to quickly find and procure hardware and software, pay-as-you-go and recurring subscription cloud technologies across various online marketplaces, including Ingram Micro Online and Ingram Micro Cloud Marketplace. HarmonyPSA automates the billing process and provides accurate, real-time views of customers’ contracts, projects and profitability.
“The acquisition of Harmony is a direct response to our MSP partners’ requests to help them quickly transform and grow a cloud services business with less risk,” said Nimesh Davé, president of CloudBlue and Ingram Micro Cloud. “We are delighted to have the Harmony team join our CloudBlue community as we expand our technology offerings.”
“We’re extremely excited to join the CloudBlue family to capitalize on our shared commitment of driving growth for our customers,” said Steve Powell, co-founder and CTO of Harmony Business Systems. “By working together, we will dramatically scale our customer base and expand our offering across various marketplaces.”
Stephen Robitaille, director of sales operations at intlx Solutions and a customer of HarmonyPSA, is enthusiastic about the platform's ability to automatically create purchase orders and generate unique reports that track project profitability on all aspects of the business. "It's made my work much easier and our business much more efficient."
More information on HarmonyPSA and how it helps accelerate the digital transformation of reseller partners is available at www.harmonypsa.com .
About CloudBlue
CloudBlue provides a hyperscale platform with hypergrowth products and services that allows providers to launch and manage an omni-product, multi-tier and multi-channel marketplace. With CloudBlue, providers can access and capitalize on a hyperconnected ecosystem of 200+ top-selling vendors, 200+ leading brands and more than 80,000 partners globally. Many of the world’s best-known software and SaaS vendors, digital service providers, technology distributors, tech manufacturers, managed services providers and value-added resellers rely on CloudBlue’s leading CloudBlue Commerce and CloudBlue Connect platforms to automate, aggregate and sell both their own cloud services as well as those from third-party vendors. CloudBlue powers more than 200 of the world’s largest provider cloud marketplaces, which collectively represent more than 30 million enterprise cloud subscriptions. More at www.cloudblue.com .
About Harmony Business Systems
Harmony Business Systems Ltd., a CloudBlue company, is the company behind HarmonyPSA, the most complete cloud professional services automation (PSA) software on the market. Purpose-built with functionality to cater to even the most complex needs of MSPs, VARs, ISVs and Professional Services Organizations, HarmonyPSA truly is the next-generation PSA system built for today’s Modern Service Provider. Amplified by CloudBlue’s powerful cloud services automation platform, HarmonyPSA empowers services organizations to scale recurring channel revenue and diminish operational complexity via its advanced product suite, which includes automated billing and reconciliation, real-time profitability analysis, an industry-leading customer support center and network operations center (NOC), and much more. To learn more, visit www.harmonypsa.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005021/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom